Study reaffirms importance and efficacy of mammography

The study, published today in Cancer Epidemiology, Biomarkers and Prevention is the largest of its kind in Australia and one of the largest in the world. It followed about 4,000 women in a study of the BreastScreen program in Western Australia.

University of Melbourne Research Fellow Dr Carolyn Nickson and colleagues from the Melbourne School of Population Health said the findings reaffirmed the importance and efficacy of mammography.

The study focused on women aged 50-69 years, who are in the target age range for screening. It included 427 cases where women had died from breast cancer and 3,650 control women who were still alive when the other women died.

The research team compared screening attendance between the two groups and found screening was much lower among women who had died from breast cancer, a finding that is consistent with a similar study from South Australia and with numerous studies from around the world. Comparison with similar studies showed an average estimate of a 49% reduced risk of dying.

Some other studies including studies from Australia claim that screening doesn't reduce risk of dying from breast cancer. However, these studies do not compare outcomes for individual women.

"Sound research methods have been used in this study. I believe it is time to move on from the debate about whether screening reduces mortality and to instead direct research resources to help improve the program for women who choose to use it," Dr Nickson said.

"It is important that Australian women have accurate information about the pros and cons of participating in BreastScreen. The findings of this study may help women decide whether to participate."

"Early detection is the key to early treatment and the free BreastScreen program is the best health service available to detect breast cancers earlier in women aged 50-69 years."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New glucose-sensitive insulin NNC2215 could transform diabetes care by lowering hypoglycemia risk